What changed
$ZLAB — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $38M | EPS $-0.46 vs $-0.53 🟢
💡 Consensus expects continued heavy cash burn and delayed profitability, but the EPS beat and growing revenue from Zejula, Optune, and new launches suggest the company is on track to narrow losses faster than modeled. The stock has been de-rated, creating an opportunity.
📉 Reward/risk: 2.2:1
🏢 Business Quality: 7/10 - Strong in-licensed pipeline with exclusive China rights to proven global drugs, solid commercial execution, but still loss-making and reliant on milestones.
📊 Valuation: fair - EV/Sales ~10x on 2025 estimates vs peers at 8-15x; DCF suggests $25 fair value assuming 30% revenue CAGR and 2028 breakeven.
🔮 Catalyst: Q4 2024 earnings beat and forward guidance
💰 Entry: $17.73, stop $14.5, target $25.0
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/ZLAB0616